Niki BioSolutions, Inc. — Form 8-K
Filed August 21, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
On July 20, 2026, Aptorum Group Limited (now Niki BioSolutions, Inc.) completed its merger with DiamiR Biosciences Corp., with Aptorum shareholders retaining ~30% ownership and DiamiR shareholders receiving 1,979,216 shares of Niki common stock. For the six months ended June 30, 2026, Niki reported a net loss of $1.3M, negative working capital of $2.5M, and operating cash outflows of $1.6M. Cash declined from $3.5M (Dec 2025) to $1.8M (June 2026). Management disclosed substantial doubt about going-concern ability within 12 months.
Why this rating
Material event: transformational M&A plus going-concern warning. DiamiR adds diagnostic capability but combined entity faces acute liquidity crisis—$1.8M cash vs. $2.5M negative working capital equals severe runway risk for $18.7M-asset company. Merger itself strategically significant; financial distress creates existential threat.
See more from August 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.